CD274 and non-small cell lung carcinoma: The first one, an analysis of patients with extensive-stage NSCLC who were treated with first-line platinum therapy and PD-1/PD-L1 inhibitors, reported that longer PFS (p = 0.028), but not OS, was predicted by NLR values ≤ 3.1 in multivariate analysis [89].